Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA User Fees: Negotiators Close To Agreement, But Backlog Is Sticking Point

Executive Summary

The generics industry does not appear satisfied with an FDA proposal to treat all applications equally under a new generic drug user fee program, preferring instead to create another, separate user fee that would clear the ANDA application backlog faster.

You may also be interested in...



GDUFA Launch Pains: Facility List Fluctuations, Back-Due Backlog Fees

FDA still has backlog fees in arrears more than two months past the payment deadline, but cannot forcibly withdraw the applications; facility listings also change consistently because industry can update them as needed.

Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline

The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.

As GDUFA Launch Nears, Is Sitting In The Backlog More Appealing?

More submissions are going into the generic drug backlog, likely because the backlog fee is expected to be less than half the GDUFA application fee.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel